Nexus Surgical and Medicare Ltd

On 24-Dec, Nexus Surgical and Medicare Ltd experienced a sharp decline in its share price, falling 15.0% to close at a new 52-week low of ₹13.26. This significant drop comes after a period of volatility and marks a reversal following four consecutive days of gains.

As of 18-Nov, Nexus Surgical and Medicare Ltd's stock price is declining at 16.80, down 2.04%, and has underperformed its sector. The stock is trading below all major moving averages, indicating a bearish trend, with a significant drop in investor participation and a concerning year-to-date decline of 39.31%.

Nexus Surgical has shown significant growth in net sales and profitability, with net sales increasing from 1.55 Cr in March 2023 to 5.72 Cr in March 2025, and profit after tax rising from 0.17 Cr to 0.50 Cr, while maintaining zero debt. The company's operating profit margin improved, reflecting a positive financial trajectory overall.

Nexus Surgical has shown significant growth in net sales and profitability, with net sales increasing from 1.55 Cr in March 2023 to 5.72 Cr in March 2025, and profit after tax rising from 0.17 Cr to 0.50 Cr during the same period, while maintaining a zero debt position. The company's earnings per share improved from -9.69 in March 2020 to 0.91 in March 2025.

As of 14-Nov, Nexus Surgical and Medicare Ltd's stock price has increased to Rs 17.98, up 8.97%, and is trading above all key moving averages, indicating a positive trend. Despite recent gains, the stock has underperformed the Sensex year-to-date, down 35.04%.

Nexus Surgical has shown significant financial growth, with net sales rising to 5.72 Cr in Mar'25 from 3.47 Cr in Mar'24, resulting in an operating profit of 0.67 Cr and a profit after tax of 0.50 Cr. The company's earnings per share improved to 0.91, reflecting enhanced shareholder value and a solid growth trajectory.

The next results date for Nexus Surgical is 14 November 2025.

As of 11-Nov, Nexus Surgical and Medicare Ltd's stock price is Rs 16.21, down 9.89% and underperforming significantly compared to the market, with a year-to-date decline of 41.44%. Despite increased delivery volume, the stock remains in a bearish trend, trading below all key moving averages.

Nexus Surgical has demonstrated significant growth, with net sales increasing from 1.55 Cr in March 2023 to 5.72 Cr in March 2025, and profitability metrics such as profit after tax rising to 0.50 Cr, resulting in a PAT margin of 8.74%. The company's total assets also grew from 0.91 Cr to 2.27 Cr, indicating a stable financial position and enhanced shareholder value.

Nexus Surgical has shown significant growth in net sales and profitability, with net sales increasing from 1.55 Cr in Mar'23 to 5.72 Cr in Mar'25, and profit after tax rising from 0.17 Cr to 0.50 Cr in the same period, alongside improvements in EPS and book value per share. The company's financial position has strengthened, reflected in its growing total assets and operating profit.

As of 29-Oct, Nexus Surgical and Medicare Ltd's stock price is Rs 17.30, down 7.88%, and has underperformed the Sensex significantly year-to-date with a decline of 37.50%. Despite a slight increase in investor participation, the stock's mixed momentum and overall poor performance compared to the market suggest ongoing downward pressure.

As of 27-Oct, Nexus Surgical and Medicare Ltd's stock is currently priced at Rs 18.50, reflecting a 5.84% increase. The stock has shown strong recent performance, outperforming its sector and gaining investor interest, despite a year-to-date decline.